'FDA Advisors Weigh Whether Alzheimer's Drug Leqembi Should Receive Full Approval, Will Make A Final Decision On July 6' - CNBC
Portfolio Pulse from Happy Mohamed
The FDA's independent advisors are reviewing Eisai and Biogen's Alzheimer's drug Leqembi for full approval, with a final decision expected on July 6. Medicare has promised to broadly cover the $26,500 per year treatment if it receives full approval.
June 09, 2023 | 3:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biogen's Alzheimer's drug Leqembi, developed with Eisai, is under FDA review for full approval. A positive decision on July 6 could lead to broader Medicare coverage and increased sales.
Biogen's stock price is likely to be positively impacted if Leqembi receives full FDA approval, as it would lead to broader Medicare coverage and increased sales. The final decision is expected on July 6, and the outcome will directly affect Biogen's revenues and market position in the Alzheimer's treatment space.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100